Pacific Biosciences of California Stock Forecast
NASDAQ: PACBIndustrialsBiotechnology: Laboratory Analytical InstrumentsUSD
Market open · Delayed 15 min · as of Oct 9, 2:11 PM ET
PACB analyst consensus
Consensus (8 analysts)
buy
Avg. price target
$2.16-9.24%
- Strong buy 0
- Buy 4
- Hold 3
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 8 Wall Street analysts covering Pacific Biosciences of California (2026-10-08), 4 rate the stock a buy or strong buy, 3 rate it a hold and 1 rate it a sell or strong sell, for a consensus rating of "buy". The average 12-month price target is $2.16, with a high estimate of $3.00 and a low estimate of $1.25. The average target implies downside of 9.2% from the current price of $2.38.
The spread between the highest and lowest targets is 140.0%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for PACB.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 4 | 50% |
| Hold | 3 | 38% |
| Sell | 0 | 0% |
| Strong sell | 1 | 13% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $1.25 | -47.48% |
| Average target | $2.16 | -9.24% |
| High target | $3.00 | +26.05% |